Vaccine

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an...

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need...

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE)...

error: Content is protected !!